Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)

Plasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears...

Full description

Bibliographic Details
Main Authors: Matteo Pedrelli, Paolo Parini, Jonas Kindberg, Jon M. Arnemo, Ingemar Bjorkhem, Ulrika Aasa, Maria Westerståhl, Anna Walentinsson, Chiara Pavanello, Marta Turri, Laura Calabresi, Katariina Öörni, Gérman Camejo, Ole Fröbert, Eva Hurt-Camejo
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S002222752100047X
id doaj-d0067720a8574924b204b6fa6db396c8
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Matteo Pedrelli
Paolo Parini
Jonas Kindberg
Jon M. Arnemo
Ingemar Bjorkhem
Ulrika Aasa
Maria Westerståhl
Anna Walentinsson
Chiara Pavanello
Marta Turri
Laura Calabresi
Katariina Öörni
Gérman Camejo
Ole Fröbert
Eva Hurt-Camejo
spellingShingle Matteo Pedrelli
Paolo Parini
Jonas Kindberg
Jon M. Arnemo
Ingemar Bjorkhem
Ulrika Aasa
Maria Westerståhl
Anna Walentinsson
Chiara Pavanello
Marta Turri
Laura Calabresi
Katariina Öörni
Gérman Camejo
Ole Fröbert
Eva Hurt-Camejo
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
Journal of Lipid Research
Ursus arctos
hibernation
lipids
apoB
lipoproteins
proteoglycans
author_facet Matteo Pedrelli
Paolo Parini
Jonas Kindberg
Jon M. Arnemo
Ingemar Bjorkhem
Ulrika Aasa
Maria Westerståhl
Anna Walentinsson
Chiara Pavanello
Marta Turri
Laura Calabresi
Katariina Öörni
Gérman Camejo
Ole Fröbert
Eva Hurt-Camejo
author_sort Matteo Pedrelli
title Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
title_short Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
title_full Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
title_fullStr Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
title_full_unstemmed Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)
title_sort vasculoprotective properties of plasma lipoproteins from brown bears (ursus arctos)
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2021-01-01
description Plasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears in winter (hibernation) and summer using size exclusion chromatography, ultracentrifugation, and electrophoresis. LDL binding to arterial proteoglycans (PGs) and plasma cholesterol efflux capacity (CEC) were also evaluated. The data collected and analyzed from bears were also compared with those from healthy humans. In bears, the cholesterol ester, unesterified cholesterol, TG, and phospholipid contents of VLDL and LDL were higher in winter than in summer. The percentage lipid composition of LDL differed between bears and humans but did not change seasonally in bears. Bear LDL was larger, richer in TGs, showed prebeta electrophoretic mobility, and had 5–10 times lower binding to arterial PGs than human LDL. Finally, plasma CEC was higher in bears than in humans, especially the HDL fraction when mediated by ABCA1. These results suggest that in brown bears the absence of early atherogenesis is likely associated with a lower affinity of LDL for arterial PGs and an elevated CEC of bear plasma.
topic Ursus arctos
hibernation
lipids
apoB
lipoproteins
proteoglycans
url http://www.sciencedirect.com/science/article/pii/S002222752100047X
work_keys_str_mv AT matteopedrelli vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT paoloparini vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT jonaskindberg vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT jonmarnemo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT ingemarbjorkhem vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT ulrikaaasa vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT mariawesterstahl vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT annawalentinsson vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT chiarapavanello vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT martaturri vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT lauracalabresi vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT katariinaoorni vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT germancamejo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT olefrobert vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
AT evahurtcamejo vasculoprotectivepropertiesofplasmalipoproteinsfrombrownbearsursusarctos
_version_ 1721443564873842688
spelling doaj-d0067720a8574924b204b6fa6db396c82021-05-12T04:09:26ZengElsevierJournal of Lipid Research0022-22752021-01-0162100065Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)Matteo Pedrelli0Paolo Parini1Jonas Kindberg2Jon M. Arnemo3Ingemar Bjorkhem4Ulrika Aasa5Maria Westerståhl6Anna Walentinsson7Chiara Pavanello8Marta Turri9Laura Calabresi10Katariina Öörni11Gérman Camejo12Ole Fröbert13Eva Hurt-Camejo14Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; For correspondence: Eva Hurt-Camejo; Matteo PedrelliDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Metabolism Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Theme Inflammation and Infection, Karolinska university Hospital, Stockholm, SwedenNorwegian Institute for Nature Research, Trondheim, Norway; Swedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, SwedenSwedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, Sweden; Department of Forestry and Wildlife Management, Inland Norway University of Applied Sciences, Campus Evenstad, Koppang, NorwayDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenDepartment of Community Medicine and Rehabilitation, Umeå University, Umeå, SwedenDivision of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenTranslational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyCentro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, ItalyAtherosclerosis Research Laboratory, Wihuri Research Institute, Helsinki, FinlandDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenSwedish University of Agricultural Sciences, Department of Wildlife, Fish, and Environmental Studies, Umeå, Sweden; Örebro University, Faculty of Health, Department of Cardiology, Örebro, SwedenDivision of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; For correspondence: Eva Hurt-Camejo; Matteo PedrelliPlasma cholesterol and triglyceride (TG) levels are twice as high in hibernating brown bears (Ursus arctos) than healthy humans. Yet, bears display no signs of early stage atherosclerosis development when adult. To explore this apparent paradox, we analyzed plasma lipoproteins from the same 10 bears in winter (hibernation) and summer using size exclusion chromatography, ultracentrifugation, and electrophoresis. LDL binding to arterial proteoglycans (PGs) and plasma cholesterol efflux capacity (CEC) were also evaluated. The data collected and analyzed from bears were also compared with those from healthy humans. In bears, the cholesterol ester, unesterified cholesterol, TG, and phospholipid contents of VLDL and LDL were higher in winter than in summer. The percentage lipid composition of LDL differed between bears and humans but did not change seasonally in bears. Bear LDL was larger, richer in TGs, showed prebeta electrophoretic mobility, and had 5–10 times lower binding to arterial PGs than human LDL. Finally, plasma CEC was higher in bears than in humans, especially the HDL fraction when mediated by ABCA1. These results suggest that in brown bears the absence of early atherogenesis is likely associated with a lower affinity of LDL for arterial PGs and an elevated CEC of bear plasma.http://www.sciencedirect.com/science/article/pii/S002222752100047XUrsus arctoshibernationlipidsapoBlipoproteinsproteoglycans